 |
Clinical Trials |
||
|
Home | Cancer Information | Care Teams | Clinical Trials | Research |
|||
|
|
|||
|
|
|
The Ireland Cancer Center is conducting a Phase II study to determine the response rate of Combretastatin (CA4P) given to patients with anaplastic cancer of the thyroid. Combretastatin represents a new class of therapeutic drugs known as vascular targeting agents. This drug has reduced blood flow to tumors in clinical trials and preclinical animal models. Patients must have regionally advanced or metastatic anaplastic carcinoma of the thyroid. Patients will receive CA4P by an intravenous infusion every week for 3 weeks followed by one week of rest. If you have a diagnosis of anaplastic thyroid cancer and are interested in the study, please answer the following questions on this form and submit it. |
|
|
|
Home | Cancer Information | Care Teams | Clinical Trials | Research Programs |
||
|
|
|||
|
11100 Euclid Avenue
Cleveland, OH 44106 |
|||
